According to the company, the device is a metered-dose dry powder inhaler featuring a fixed-dose combination of glycopyrronium bromide, indacaterol, and ciclesonide; the company noted that there are currently no other medications worldwide containing this specific combination of active ingredients.

Specialists from the Ministry of Health’s National Medical Research Center for Phthisiopulmonology and Infectious Diseases estimate that the number of asthma patients in Russia is approaching 10 million.

To reduce the risk of exacerbations, these patients require treatment that simultaneously dilates the bronchi and reduces inflammation.

The drug’s developers pointed out that combining three components into a single device eliminates the need for patients to use multiple inhalers. They believe this will significantly improve adherence to prescribed treatment—a major challenge in managing chronic respiratory diseases.

nmr/gfa